Genomeditech (Shanghai) Co.,Ltd. Order: 021-68455258/50432826/50432825

Toll-free: 400 627 9288

Email: service@genomeditech.com

# Cynomolgus ALPI Protein; His Tag

#### **Product Information**

**Product Name** Cynomolgus ALPI Protein; His Tag

**Storage temp.** Store at  $\leq$  -70°C, stable for 6 months after receipt.

Recommend to aliquot the protein into smaller quantities for

optimal storage. Please minimize freeze-thaw cycles.

Catalog# / Size GM-84643RP-100 / 100 μg

GM-84643RP-1000 / 1 mg

### **Protein Information**

Alternative Names IAP

Source Cynomolgus ALPI Protein; His Tag (GM-84643RP) is expressed from human

293 cells (HEK-293). It contains AA Ile20-Asp502 (Accession #

A0A2K5VFX3).

This protein carries a His tag at the C-terminus.

**Purity** > 90% as determined by SDS-PAGE

Endotoxin < 1 EU/μg, determined by LAL gel clotting assay

Predicted Mol Mass 54.2 KDa

**Formulation** Supplied as a 0.2 μm filtered solution of PBS, pH7.4.

**Description** Intestinal alkaline phosphatase (ALPI) is an enzyme primarily encoded by the

ALPI gene in the human body. This enzyme is mainly present in the small intestine and the liver, and can also be found in other tissues, although in smaller amounts. The main function of intestinal alkaline phosphatase in the small intestine is to assist in the digestion and absorption of phosphates and fats from food. Additionally, it is used as one of the clinical diagnostic markers for detecting intestinal diseases or bone disorders. Research on ALPI in human diseases also suggests that it may play a role in certain intestinal diseases and inflammatory processes. The gene responsible for IAP is mapped on the long arm of chromosome 2. IAP is a heat stable isozyme and more active at pH 9.7. Unlike other AP's the side chain of IAP lacks terminal sialic acid residues. IAP is essential for lipids absorption and is involved in reducing inflammation. IAP suppresses inflammation, particularly by modifying the gut microflora and dephosphorylating LPS. Any alteration in IAP expression and activity increases the vulnerability to inflammation. Inflammatory bowel disease (IBD) is an indication of a condition where the patient's endogenous IAP production and activity are reduced. Exogenous IAP injection may be a good option for treating IBD and other disorders caused by the disruption of gut microbiota.


Version:3.3 Revision Date:25/12/2023

Genomeditech (Shanghai) Co.,Ltd. Order: 021-68455258/50432826/50432825

Toll-free: 400 627 9288

Email: service@genomeditech.com


## **SDS-PAGE**



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

## **Bioactivity-ELISA**

Cynomolgus ALPI Protein; His Tag, ELISA 0.1µg Cynomolgus ALPI Protein; His Tag of per well



Cynomolgus ALPI Protein; His Tag (Catalog # GM-84643RP) was immobilized at 1  $\mu$ g/ml (100  $\mu$ L/well). Increasing concentrations of Anti-His mIgG2a Antibody (Catalog # GM-59493AB) were added.